Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • CANCER-CELLS  (2)
  • 1
    Keywords: CANCER ; CANCER CELLS ; CELLS ; EXPRESSION ; radiotherapy ; SURVIVAL ; tumor ; TUMOR-CELLS ; AGENTS ; BLOOD ; CELL ; Germany ; THERAPY ; SAMPLE ; SAMPLES ; transcription ; PATIENT ; treatment ; bone marrow ; BONE-MARROW ; STAGE ; resistance ; colorectal cancer ; COLORECTAL-CANCER ; EFFICACY ; RATES ; chemotherapy ; CANCER-CELLS ; CANCER-PATIENTS ; CARCINOMAS ; CYTOKERATIN-20 ; POLYMERASE-CHAIN-REACTION ; adenocarcinoma ; BINARY ; ELIMINATION ; neoadjuvant treatment
    Abstract: Objective: To compare the detection rates for rectal cancer cells in blood and bone marrow in patients with or without preoperative chemoradiation.Summary Background Data: Previous reports have postulated a resistance of disseminated tumor cells to antiproliferative agents because of tumor cell dormancy.Methods: Blood samples from 142 patients (pre, intra-, and postoperative samples) and bone marrow samples from 127 patients undergoing resection of rectal adenocarcinoma were analyzed for tumor cells using a cytokeratin (CK) 20-reverse transcription polymerase chain reaction. The results were stratified according to preoperative therapy.Results: In patients without preoperative chemoradiation, tumor cell detection in blood and bone marrow correlated to tumor stage (Cochran Armitage trend test, P 〈 0.05). Tumor cells were detected in 34 of 103 (33%) bone marrow and 65 of 117 (55.6%) blood samples of patients without neoadjuvant treatment versus in 4 of 24 (16.7%) bone marrow and in 10 of 25 (40%) blood samples of patients with neoadjuvant treatment. The tumor cell detection rate was significantly lower in the group having undergone chemoradiation (binary logistic regression analysis, P 〈 0.05). The overall and disease-free survival were significantly worse in patients with tumor cell detection in the bone marrow after neoadjuvant therapy.Conclusions: Preoperative chemoradiation is associated with a decreased detection rate of rectal cancer cells in blood and bone marrow. These findings may explain the observed clinical benefit of patients with rectal cancer receiving chemoradiation. This is the first study suggesting that detection of disseminated rectal cancer cells may be useful for assessing the efficacy of neoadjuvant therapy
    Type of Publication: Journal article published
    PubMed ID: 14501498
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; CANCER CELLS ; CELLS ; ENDOTHELIAL-CELLS ; EXPRESSION ; GROWTH ; IN-VITRO ; INVASION ; proliferation ; tumor ; TUMOR-CELLS ; Germany ; VITRO ; DISEASE ; GENE ; GENES ; TISSUE ; TUMORS ; PATIENT ; prognosis ; INDUCTION ; CONTRAST ; fibroblasts ; GLYCOPROTEIN ; PROGRESSION ; immunohistochemistry ; ASSAY ; CANCER-CELLS ; EXTRACELLULAR-MATRIX ; NEOPLASTIC PROGRESSION ; POLYMERASE-CHAIN-REACTION ; adenocarcinoma ; OVEREXPRESSION ; POOR-PROGNOSIS ; pancreatic cancer ; chronic pancreatitis ; HUMAN BREAST-CANCER ; SERUM ; MATRIX ; quantitative polymerase chain reaction ; PANCREATIC-CANCER ; DUCTAL ADENOCARCINOMA ; extracellular matrix ; OLIGONUCLEOTIDE ; interaction ; TARGET GENE ; TARGET GENES ; ANTISENSE OLIGONUCLEOTIDE ; MALIGNANT-TUMORS ; EXTRACELLULAR-MATRIX PROTEINS ; DISEASE PROGRESSION ; CYSTEINE SPARC ; DEGRADING PROTEASES ; ESOPHAGEAL-CARCINOMA ; I COLLAGEN ; MATRICELLULAR PROTEIN ; SPARC EXPRESSION
    Abstract: Objective: We sought to examine the expression and functional role of osteonectin in primary and metastatic pancreatic ductal adenocarcinoma (PDAC). Background: The glycoprotein osteonectin plays a vital role in cell-matrix interactions and is involved in various biologic processes. Overexpression of osteonectin is present in malignant tumors and correlates with disease progression and poor prognosis. Methods: Expression of osteonectin was analyzed by quantitative polymerase chain reaction and immunohistochemistry in pancreatic tissues and by enzyme-linked immunosorbent assay in the serum of patients and donors. Recombinant osteonectin and specific antisense oligonucleotides were used to examine the effects of osteonectin on induction of target genes, and on proliferation and invasiveness of pancreatic cancer cells. Results: There was a 31-fold increase in osteonectin mRNA levels in PDAC and a 16-fold increase in chronic pancreatitis as compared with the normal pancreas (P 〈 0.01). By immunohistochemistry, faint immunoreactivity was detected in the normal pancreas. In contrast, strong staining of the cancer cells was observed in addition to extensive osteonectin immunoreactivity in surrounding fibroblasts and in the extracellular matrix. In metastatic tissues, strong immunoreactivity was observed in fibroblasts and in extracellular matrix surrounding metastatic cancer cells, whereas the signal was absent in most tumor cells. In vitro studies showed that osteonectin was able to inhibit cancer cell growth while promoting invasiveness of pancreatic tumor cells. Conclusion: Osteonectin is markedly overexpressed in pancreatic cancer and has the potential to increase the invasiveness of pancreatic cancer cells
    Type of Publication: Journal article published
    PubMed ID: 16041213
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...